Status:
COMPLETED
Renal Function Among Thalassemia Patients Treated by a Oral Chelator Deferasirox
Lead Sponsor:
HaEmek Medical Center, Israel
Conditions:
Thalassemia
Iron Overload
Eligibility:
All Genders
1-45 years
Brief Summary
Thalassemia Major patients developed Iron Overload due to blood transfusions and intestinal iron absorption. Renal function caused by Iron overload was studied in a previous study and shows principall...
Detailed Description
Patients with Thalassemia Major. The laboratory tests that will be studied are: Urine dip stick, Urea, Creatinine, Na, K, Uric Acid, Calcium, Phosphorus in serum and urine, and N acetyl-b-D-glucosamin...
Eligibility Criteria
Inclusion
- Inclusion Criteria:
- Patients with Thalassemia Major or Intermedia treated by Iron chelators or by blood transfusions without treatment with iron chelators
- Exclusion criteria:
- None relevant
Exclusion
Key Trial Info
Start Date :
March 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2015
Estimated Enrollment :
36 Patients enrolled
Trial Details
Trial ID
NCT01905774
Start Date
March 1 2011
End Date
August 1 2015
Last Update
September 1 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ha'Emek Medical Center
Afula, Israel, 18101